Dr. Jan M. Lundberg MD, PhD

Dr. Jan M. Lundberg serves as Chair of IAG’s Scientific Advisory Board and Client Advisory Board, and as a Non-Executive Director on IAG’s corporate board, roles he has held since joining IAG in 2018. In this capacity he leads IAG’s distinguished board of in-house scientists, imaging experts, and academic collaborators, works closely with biotech and pharma partners to provide critical assessments of novel therapeutic agents, and advises on the use of advanced imaging technologies across therapeutic areas. He is co-founder of Aerocrine AB and currently serves on the boards of directors of Anocca, Ardelyx, Betagenon, Metabolon, and TB Alliance. He previously served as Executive Vice President, Science and Technology and President of Lilly Research Laboratories at Eli Lilly and Company (January 2010 to June 2018), and as Global Head of Discovery Research at AstraZeneca (January 1999 to November 2009).

Dr. Lundberg has over 27 years of executive leadership experience in global pharmaceutical R&D, having been involved in more than 200 candidate drugs and 30 approved products across multiple therapeutic areas. Named approved products from supplied sources include Brilinta, Iressa, Nexium, Taltz, Trulicity, Verzenio, and Tirzepatide (Mounjaro), and he was involved in the positive Phase 3 trial for donanemab in Alzheimer’s disease. His expertise spans drug discovery and development, early drug efficacy assessment, amyloid and tau PET imaging for Alzheimer’s research, smart patient recruitment, and predictive analysis of advanced treatment manifestations.

His academic research at the Karolinska Institutet, where he was Professor of Pharmacology from 1993 to 1996, focused on neuropeptide pharmacology — specifically neuropeptide Y (NPY), substance P, calcitonin gene-related peptide (CGRP), and their roles in sympathetic nervous system function, cardiovascular physiology, and sensory neuroscience. He is a highly cited author in this field. He developed novel approaches to clinical trial design during his AstraZeneca tenure, including radiomics and integrated multi-omics approaches to patient segmentation and novel clinical outcome measures to accelerate early trial timelines. He is co-creator of proprietary research approaches and has VC investment experience from MedImmune, Rhenman, and Lilly Ventures.

Dr. Lundberg has been involved in the development and clinical trial programs of more than 200 candidate drugs across multiple therapeutic areas, with 30 approved products resulting from these programs. Specific named programs from supplied sources include: Brilinta (ticagrelor, AstraZeneca, cardiovascular), Iressa (gefitinib, AstraZeneca, oncology), Nexium (esomeprazole, AstraZeneca, gastroenterology), Taltz (ixekizumab, Eli Lilly, immunology), Trulicity (dulaglutide, Eli Lilly, diabetes), Verzenio (abemaciclib, Eli Lilly, oncology), Tirzepatide/Mounjaro (Eli Lilly, diabetes/obesity), and donanemab (Eli Lilly, Alzheimer’s disease, positive Phase 3). His clinical trial leadership spanned Phases I through III across discovery, early development, and late-stage programs at both AstraZeneca and Eli Lilly.

At IAG, he advises on the use of advanced imaging technologies in clinical trials, including amyloid and tau PET imaging for Alzheimer’s disease trials, and contributes to IAG’s strategy for early drug efficacy assessment and smart patient recruitment.

Dr. Lundberg has 234 publications listed on ResearchGate and is a highly cited author in neuropeptide pharmacology.He has served on the boards of AstraZeneca, Eli Lilly, Metabolon, IAG, Anocca, TB Alliance, Betagenon, Ferring, and Ardelyx, and has held VC positions with MedImmune, Rhenman, and Lilly Ventures. He is co-founder of Aerocrine AB. His published academic work has appeared in journals including Acta Physiologica Scandinavica, Clinical Science, Annals of the New York Academy of Sciences, and Critical Care Medicine.

Dr. Lundberg completed his medical training at the University of Gothenburg and his doctorate in Pharmacology at the Karolinska Institutet in Stockholm. He was appointed Professor of Pharmacology at the Karolinska Institutet, Department of Pharmacology, from 1993 to 1996. He then moved into industry, serving as Head of Preclinical Research at Astra AB from January 1996 to 1999, before the Astra-Zeneca merger, following which he became Global Head of Discovery Research at AstraZeneca from January 1999 to November 2009. He then joined Eli Lilly as President of Lilly Research Laboratories and Head of R&D from January 2010 to June 2018.